1. Home
  2. MDGL vs IESC Comparison

MDGL vs IESC Comparison

Compare MDGL & IESC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • IESC
  • Stock Information
  • Founded
  • MDGL 2011
  • IESC 1997
  • Country
  • MDGL United States
  • IESC United States
  • Employees
  • MDGL N/A
  • IESC N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • IESC Engineering & Construction
  • Sector
  • MDGL Health Care
  • IESC Industrials
  • Exchange
  • MDGL Nasdaq
  • IESC Nasdaq
  • Market Cap
  • MDGL 6.1B
  • IESC 5.4B
  • IPO Year
  • MDGL N/A
  • IESC 1998
  • Fundamental
  • Price
  • MDGL $304.86
  • IESC $290.23
  • Analyst Decision
  • MDGL Strong Buy
  • IESC
  • Analyst Count
  • MDGL 9
  • IESC 0
  • Target Price
  • MDGL $420.63
  • IESC N/A
  • AVG Volume (30 Days)
  • MDGL 305.4K
  • IESC 183.5K
  • Earning Date
  • MDGL 08-06-2025
  • IESC 08-01-2025
  • Dividend Yield
  • MDGL N/A
  • IESC N/A
  • EPS Growth
  • MDGL N/A
  • IESC 79.94
  • EPS
  • MDGL N/A
  • IESC 11.95
  • Revenue
  • MDGL $317,383,000.00
  • IESC $3,127,688,000.00
  • Revenue This Year
  • MDGL $286.17
  • IESC N/A
  • Revenue Next Year
  • MDGL $64.17
  • IESC N/A
  • P/E Ratio
  • MDGL N/A
  • IESC $24.41
  • Revenue Growth
  • MDGL N/A
  • IESC 21.53
  • 52 Week Low
  • MDGL $200.63
  • IESC $129.16
  • 52 Week High
  • MDGL $377.46
  • IESC $320.09
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 61.70
  • IESC 65.42
  • Support Level
  • MDGL $277.64
  • IESC $280.29
  • Resistance Level
  • MDGL $314.22
  • IESC $295.00
  • Average True Range (ATR)
  • MDGL 11.62
  • IESC 10.53
  • MACD
  • MDGL 3.11
  • IESC 0.18
  • Stochastic Oscillator
  • MDGL 82.64
  • IESC 90.84

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About IESC IES Holdings Inc.

IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.

Share on Social Networks: